Noah Medical’s Galaxy System Achieves First U.S. Robotic Bronchoscopy

Medical robotics company Noah Medical has achieved the first use of its Galaxy system in the U.S., conducted at the University of Chicago Medicine by Dr. Kyle Hogarth. The procedure marks U.S. commercial release of the robotic navigation system and follows its recent U.S. Food and Drug Administration (FDA) clearance.
 
The Galaxy system was designed for more confident navigation and location of lung nodules during biopsy, as part of a more effective, efficient bronchoscopy procedure. According to the company, based on a recent first-in-human trial, physician feedback has been overwhelmingly positive regarding the device’s TiLT+ technology with integrated tomosynthesis and augmented fluoroscopy, its single-use disposable bronchoscope, and a small, compact footprint, which allows for easy integration into most bronchoscopy suites.
 
“The Galaxy System is the first robot for peripheral lung navigation that includes integrated imaging, which is the solution bronchoscopists have been asking for,” Kyle Hogarth, MD told the press. “We are excited to be the first hospital in the United States to implement this next generation robotic solution for our patients which we believe will improve and expedite the early diagnosis and treatment of lung cancer.”
 
“Congratulations to Dr. Hogarth and the team at UChicago Medicine for completing this milestone achievement in robotic bronchoscopy,” added Jian Zhang, Ph.D., Noah Medical founder and CEO. “We designed the Galaxy System in collaboration with physicians to provide unique clinical value to patients and improved procedural efficiency. We are thrilled to introduce the platform at UChicago Medicine, a pioneer in using life-saving technologies to fight lung cancer.”
 
The Journal of Bronchology & Interventional Pulmonology recently published Noah Medical’s MATCH Study, testing the Galaxy system’s “Tool-in-Lesion” accuracy. The study found the robotic platform’s TiLT+ technology achieves 100% successful navigation to lesion, 100% diagnostic yield and 95% tool-in-lesion accuracy.